|
Bakken, A. F., M. M. Thaler, and R. Schmid. 1972. Metabolic regulation of heme catabolism and bilirubin production. I. Hormonal control of hepatic heme oxygenase activity. J. Clin. Invest. 51: 530-536
Bauer, I., H. Rensing, A. Florax, C. Ulrich, G. Pistorius, H. Redl, and M. Bauer. 2003. Expression pattern and regulation of heme oxygenase-1/heat shock protein 32 in human liver cells. Shock 20:116-122.
BBell, R. L., D. A. Kennerly, N. Stanford, and P. W. Majerus. 1979. Diglyceride lipase: a pathway for arachidonate release from human platelets. Proc.Natl.Acad.Sci.U.S.A 76:3238-3241.
Billah, M. M., E. G. Lapetina, and P. Cuatrecasas. 1981. Phospholipase A2 activity specific for phosphatidic acid. A possible mechanism for the production of arachidonic acid in platelets. J.Biol.Chem. 256:5399-5403.
Booyse, F. M. and M. E. Rafelson, Jr. 1972. Regulation and mechanism of platelet aggregation. Ann.N.Y.Acad.Sci. 201:37-60.
Boullin, D. J., A. R. Green, and K. S. Price. 1972. The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1. J.Physiol 221:415-426.
Cairns, J. A. 1987. Clinical trials of antiplatelet drug therapy in acute myocardial infarction, unstable angina, and aortocoronary bypass surgery. Cardiovasc.Clin. 18:231-246.
Cole, B., G. A. Robison, and R. C. Hartmann. 1971. The role of cyclic AMP in platelet function. Ann.N.Y.Acad.Sci. 185:477-487.
Dayal, S. D., G. Hasko, Q. Lu, D. Z. Xu, J. M. Caruso, J. T. Sambol, and E. A. Deitch. 2002. Trauma/hemorrhagic shock mesenteric lymph upregulates adhesion molecule expression and IL-6 production in human umbilical vein endothelial cells. Shock 17:491-495.
Demolis, J. L., A. Robert, M. Mouren, C. Funck-Brentano, and P. Jaillon. 1993b. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J.Cardiovasc.Pharmacol. 22:711-716.
Demolis, J. L., A. Robert, M. Mouren, C. Funck-Brentano, and P. Jaillon. 1993a. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J.Cardiovasc.Pharmacol. 22:711-716.
Denu, J. M. 2005. The Sir 2 family of protein deacetylases. Curr.Opin.Chem.Biol. 9:431-440.
Duru, S., U. Koca, S. Oztekin, C. Olguner, A. Kar, C. Coker, C. Ulukus, C. Tascl, and Z. Elar. 2005. Antithrombin III pretreatment reduces neutrophil recruitment into the lung and skeletal muscle tissues in the rat model of bilateral lower limb ischemia and reperfusion: a pilot study. Acta Anaesthesiol.Scand. 49:1142-1148.
Feijge, M. A., K. Ansink, K. Vanschoonbeek, and J. W. Heemskerk. 2004. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Biochem.Pharmacol. 67:1559-1567.
Feng, X., B. Ren, W. Xie, Z. Huang, J. Liu, R. Guan, M. Duan, and J. Xu. 2006. Influence of hydroxyethyl starch 130/0.4 in pulmonary neutrophil recruitment and acute lung injury during polymicrobial sepsis in rats. Acta Anaesthesiol.Scand. 50:1081-1088.
Feoktistov, I. A., S. Paul, A. S. Hollister, D. Robertson, and I. Biaggioni. 1992. Role of cyclic AMP in adenosine inhibition of intracellular calcium rise in human platelets. Comparison of adenosine effects on thrombin- and epinephrine-induced platelet stimulation. Am.J.Hypertens. 5:147S-153S.
Geiger, J., C. Nolte, E. Butt, S. O. Sage, and U. Walter. 1992. Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc.Natl.Acad.Sci.U.S.A 89:1031-1035.
Gerrard, J. M. 1988. Platelet aggregation: cellular regulation and physiologic role. Hosp.Pract.(Off Ed) 23:89-4, 107.
Guarente, L. 2006. Sirtuins as potential targets for metabolic syndrome. Nature 444:868-874.
Guo, R. F., N. C. Riedemann, I. J. Laudes, V. J. Sarma, R. G. Kunkel, K. A. Dilley, J. D. Paulauskis, and P. A. Ward. 2002. Altered neutrophil trafficking during sepsis. J.Immunol. 169:307-314.
Haigis, M. C. and L. P. Guarente. 2006. Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. Genes Dev. 20:2913-2921.
Hankey, G. J. and J. W. Eikelboom. 2003. Antiplatelet drugs. Med.J.Aust. 178:568-574.
Harker, L. A., R. Ross, and J. Glomset. 1976. Role of the platelet in atherogenesis. Ann.N.Y.Acad.Sci. 275:321-329. Hettasch, J. M. and G. C. Le Breton. 1987. Modulation of Ca2+ fluxes in isolated platelet vesicles: effects of cAMP-dependent protein kinase and protein kinase inhibitor on Ca2+ sequestration and release. Biochim.Biophys.Acta 931:49-58.
Hirose, H., S. Mashiko, T. Kimura, F. Ishida, N. Mochizuki, T. Nishibe, and M. Nishikibe. 2000. Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects. J.Cardiovasc.Pharmacol. 35:586-594.
Iida, M., K. Watanabe, M. Tsurufuji, K. Takaishi, Y. Iizuka, and S. Tsurufuji. 1992. Level of neutrophil chemotactic factor CINC/gro, a member of the interleukin-8 family, associated with lipopolysaccharide-induced inflammation in rats. Infect.Immun. 60:1268-1272.
Jackson, S. P., W. S. Nesbitt, and S. Kulkarni. 2003. Signaling events underlying thrombus formation. J.Thromb.Haemost. 1:1602-1612.
Jin, Y. R., C. K. Ryu, C. K. Moon, M. R. Cho, and Y. P. Yun. 2004. Inhibitory effects of J78, a newly synthesized 1,4-naphthoquinone derivative, on experimental thrombosis and platelet aggregation. Pharmacology 70:195-200.
Kang, W. S., K. H. Chung, J. H. Chung, J. Y. Lee, J. B. Park, Y. H. Zhang, H. S. Yoo, and Y. P. Yun. 2001. Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase. J.Cardiovasc.Pharmacol. 38:875-884.
Katsube, N., K. Sakaguchi, B. Fujitani, and H. Aishita. 1993. Anti-platelet and anti-thrombotic effects of OP-41483.alpha-CD, a prostacyclin analogue, in experimental animals. Prostaglandins Leukot.Essent.Fatty Acids 49:795-804.
Khadaroo, R. G., J. Fan, K. A. Powers, B. Fann, A. Kapus, and O. D. Rotstein. 2004. Impaired induction of IL-10 expression in the lung following hemorrhagic shock. Shock 22:333-339.
Kim, I. A., J. H. Shin, I. H. Kim, J. H. Kim, J. S. Kim, H. G. Wu, E. K. Chie, S. W. Ha, C. I. Park, and G. D. Kao. 2006. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin.Cancer Res. 12:940-949.
Kimura, Y. and K. Yasunaga. 1980. Interaction of prostaglandin and cyclic AMP involved in regulation of platelet function. Nippon Ketsueki Gakkai Zasshi 43:1130-1138.
Kira, S., T. Daa, K. Kashima, M. Mori, T. Noguchi, and S. Yokoyama. 2005. Mild hypothermia reduces expression of intercellular adhesion molecule-1 (ICAM-1) and the accumulation of neutrophils after acid-induced lung injury in the rat. Acta Anaesthesiol.Scand. 49:351-359.
Ko, F. N., S. J. Sheu, Y. M. Liu, T. F. Huang, and C. M. Teng. 1990. Inhibition of rabbit platelet aggregation by 1,4-naphthoquinones. Thromb.Res. 57:453-463.
Kruszewski, M. and I. Szumiel. 2005. Sirtuins (histone deacetylases III) in the cellular response to DNA damage--facts and hypotheses. DNA Repair (Amst) 4:1306-1313.
Lapetina, E. G. 1986. Incorporation of synthetic 1,2-diacylglycerol into platelet phosphatidylinositol is increased by cyclic AMP. FEBS Lett. 195:111-114.
Lazarowski, E. R. and E. G. Lapetina. 1989. Activation of platelet phospholipase C by fluoride is inhibited by elevation of cyclic AMP. Biochem.Biophys.Res.Commun. 158:440-444.
Lerea, K. M., J. A. Glomset, and E. G. Krebs. 1987b. Agents that elevate cAMP levels in platelets decrease thrombin binding. J.Biol.Chem. 262:282-288.
Lerea, K. M., J. A. Glomset, and E. G. Krebs. 1987a. Agents that elevate cAMP levels in platelets decrease thrombin binding. J.Biol.Chem. 262:282-288.
Li, Z., J. Ajdic, M. Eigenthaler, and X. Du. 2003. A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans. Blood 101:4423-4429.
li-Youcef, N., M. Lagouge, S. Froelich, C. Koehl, K. Schoonjans, and J. Auwerx. 2007. Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann.Med. 39:335-345.
Liu, F. C., Y. J. Day, J. T. Liou, Y. T. Lau, and H. P. Yu. 2008. Sirtinol attenuates hepatic injury and pro-inflammatory cytokine production following trauma-hemorrhage in male Sprague-Dawley rats. Acta Anaesthesiol.Scand. 52:635-640.
Longo, V. D. and B. K. Kennedy. 2006. Sirtuins in aging and age-related disease. Cell 126:257-268.
Maier, M., H. Strobele, J. Voges, C. Bauer, and I. Marzi. 2003. Attenuation of leukocyte adhesion by recombinant TNF-binding protein after hemorrhagic shock in the rat. Shock 19:457-461.
Malech, H. L. and J. I. Gallin. 1987. Current concepts: immunology. Neutrophils in human diseases. N.Engl.J.Med. 317:687-694.
Michan, S. and D. Sinclair. 2007. Sirtuins in mammals: insights into their biological function. Biochem.J. 404:1-13.
Minkes, M., N. Stanford, M. M. Chi, G. J. Roth, A. Raz, P. Needleman, and P. W. Majerus. 1977. Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions. J.Clin.Invest 59:449-454.
Mustard, J. F., M. A. Packham, and R. L. Kinlough-Rathbone. 1990. Platelets, blood flow, and the vessel wall. Circulation 81:I24-I27.
Neugebauer, R. C., U. Uchiechowska, R. Meier, H. Hruby, V. Valkov, E. Verdin, W. Sippl, and M. Jung. 2008. Structure-Activity Studies on Splitomicin Derivatives as Sirtuin Inhibitors and Computational Prediction of Binding Mode. J.Med.Chem.
Olanders, K., A. Borjesson, X. Zhao, and R. Andersson. 2005. Effects of anticoagulant treatment on intestinal ischaemia and reperfusion injury in rats. Acta Anaesthesiol.Scand. 49:517-524.
Ota, H., E. Tokunaga, K. Chang, M. Hikasa, K. Iijima, M. Eto, K. Kozaki, M. Akishita, Y. Ouchi, and M. Kaneki. 2006. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25:176-185.
Posakony, J., M. Hirao, and A. Bedalov. 2004. Identification and characterization of Sir2 inhibitors through phenotypic assays in yeast. Comb.Chem.High Throughput.Screen. 7:661-668.
Rajtar, G., C. Cerletti, M. N. Castagnoli, V. Bertele, and G. G. de. 1985. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors. Biochem.Pharmacol. 34:307-310.
Rhee, S. G., C. W. Lee, and D. Y. Jhon. 1993. Phospholipase C isozymes and modulation by cAMP-dependent protein kinase. Adv.Second Messenger Phosphoprotein Res. 28:57-64. Salzman, E. W. 1972. Cyclic AMP and platelet function. N.Engl.J.Med. 286:358-363. Shah, B. H., Z. Nawaz, S. A. Pertani, A. Roomi, H. Mahmood, S. A. Saeed, and A. H. Gilani. 1999. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem.Pharmacol. 58:1167-1172.
Shanley, T. P., H. Schmal, R. L. Warner, E. Schmid, H. P. Friedl, and P. A. Ward. 1997. Requirement for C-X-C chemokines (macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant) in IgG immune complex-induced lung injury. J.Immunol. 158:3439-3448.
Shen, A. Y., M. H. Huang, C. M. Teng, and J. S. Wang. 1999. Inhibition of 2-P-mercaptophenyl-1,4-naphthoquinone on human platelet function. Life Sci. 65:45-53.
Shimizu, T., H. P. Yu, Y. C. Hsieh, M. A. Choudhry, T. Suzuki, K. I. Bland, and I. H. Chaudry. 2007. Flutamide attenuates pro-inflammatory cytokine production and hepatic injury following trauma-hemorrhage via estrogen receptor-related pathway. Ann.Surg. 245:297-304.
Siess, W. 1989. Molecular mechanisms of platelet activation. Physiol Rev. 69:58-178.
Smith, J. S., J. Avalos, I. Celic, S. Muhammad, C. Wolberger, and J. D. Boeke. 2002. SIR2 family of NAD(+)-dependent protein deacetylases. Methods Enzymol. 353:282-300.
Sun, B., S. N. Le, S. Lin, M. Fong, M. Guertin, Y. Liu, N. N. Tandon, M. Yoshitake, and J. Kambayashi. 2002. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. J.Cardiovasc.Pharmacol. 40:577-585.
Tamakuma, S., M. Ogawa, N. Aikawa, T. Kubota, H. Hirasawa, A. Ishizaka, N. Taenaka, C. Hamada, S. Matsuoka, and T. Abiru. 2004. Relationship between neutrophil elastase and acute lung injury in humans. Pulm.Pharmacol.Ther. 17:271-279.
Tamion, F., V. Richard, G. Bonmarchand, J. Leroy, J. P. Lebreton, and C. Thuillez. 2001. Induction of heme-oxygenase-1 prevents the systemic responses to hemorrhagic shock. Am.J.Respir.Crit Care Med. 164:1933-1938.
Taylor, D. M., M. M. Maxwell, R. Luthi-Carter, and A. G. Kazantsev. 2008. Biological and potential therapeutic roles of sirtuin deacetylases. Cell Mol.Life Sci. 65:4000-4018. Tobelem, G. 1989. [Mechanism of platelet aggregation and mode of action of platelet antiaggregants]. Rev.Prat. 39:2219-2222.
von Andrian, U. H., J. D. Chambers, L. M. McEvoy, R. F. Bargatze, K. E. Arfors, and E. C. Butcher. 1991. Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte beta 2 integrins in vivo. Proc.Natl.Acad.Sci.U.S.A 88:7538-7542.
von, H. P. and C. Weber. 2007. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ.Res. 100:27-40.
Vorchheimer, D. A. and R. Becker. 2006. Platelets in atherothrombosis. Mayo Clin.Proc. 81:59-68. Wagner, D. D. and P. C. Burger. 2003. Platelets in inflammation and thrombosis. Arterioscler.Thromb.Vasc.Biol. 23:2131-2137.
Wallis, R. B. and D. Zelaschi. 1980. Differential effects of cyclo-oxygenase inhibitors and thromboxane synthase inhibitors on rabbit platelet aggregation: evidence for the importance of prostaglandin endoperoxides as mediators in arachidonate-induced aggregation but not in collagen-induced aggregation. Biochem.Soc.Trans. 8:726-727.
Wang, P., Z. F. Ba, M. C. Lu, A. Ayala, J. M. Harkema, and I. H. Chaudry. 1994. Measurement of circulating blood volume in vivo after trauma-hemorrhage and hemodilution. Am.J.Physiol 266:R368-R374.
Wang, T. Y., C. V. Hussey, E. A. Sasse, and J. E. Fobian. 1978. Human platelet aggregation and cAMP system--cAMP level, adenyl cyclase, phosphodiesterase. Ann.Clin.Lab Sci. 8:403-412.
Wickel, D. J., W. G. Cheadle, M. A. Mercer-Jones, and R. N. Garrison. 1997. Poor outcome from peritonitis is caused by disease acuity and organ failure, not recurrent peritoneal infection. Ann.Surg. 225:744-753.
Xing, M., S. Post, R. S. Ostrom, M. Samardzija, and P. A. Insel. 1999. Inhibition of phospholipase A2-mediated arachidonic acid release by cyclic AMP defines a negative feedback loop for P2Y receptor activation in Madin-Darby canine kidney D1 cells. J.Biol.Chem. 274:10035-10038.
Xu, D. Z., Q. Lu, C. A. Adams, A. C. Issekutz, and E. A. Deitch. 2004. Trauma-hemorrhagic shock-induced up-regulation of endothelial cell adhesion molecules is blunted by mesenteric lymph duct ligation. Crit Care Med. 32:760-765.
Yamamoto, H., K. Schoonjans, and J. Auwerx. 2007. Sirtuin functions in health and disease. Mol.Endocrinol. 21:1745-1755.
Yang, S. R., J. Wright, M. Bauter, K. Seweryniak, A. Kode, and I. Rahman. 2007. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am.J.Physiol Lung Cell Mol.Physiol 292:L567-L576.
Yang, S. R., J. Wright, M. Bauter, K. Seweryniak, A. Kode, and I. Rahman. 2007e. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am.J.Physiol Lung Cell Mol.Physiol 292:L567-L576.
Yu, H. P., M. A. Choudhry, T. Shimizu, Y. C. Hsieh, M. G. Schwacha, S. Yang, and I. H. Chaudry. 2006. Mechanism of the salutary effects of flutamide on intestinal myeloperoxidase activity following trauma-hemorrhage: up-regulation of estrogen receptor-{beta}-dependent HO-1. J.Leukoc.Biol. 79:277-284.
Yu, H. P., Y. C. Hsieh, T. Suzuki, T. Shimizu, M. A. Choudhry, M. G. Schwacha, and I. H. Chaudry. 2006. Salutary effects of estrogen receptor-beta agonist on lung injury after trauma-hemorrhage. Am.J.Physiol Lung Cell Mol.Physiol 290:L1004-L1009.
Yu, H. P., T. Shimizu, Y. C. Hsieh, T. Suzuki, M. A. Choudhry, M. G. Schwacha, and I. H. Chaudry. 2006. Tissue-specific expression of estrogen receptors and their role in the regulation of neutrophil infiltration in various organs following trauma-hemorrhage. J.Leukoc.Biol. 79:963-970.
Yu, H. P., S. Yang, M. A. Choudhry, Y. C. Hsieh, K. I. Bland, and I. H. Chaudry. 2005. Mechanism responsible for the salutary effects of flutamide on cardiac performance after trauma-hemorrhagic shock: Upregulation of cardiomyocyte estrogen receptors. Surgery 138:85-92.
Yu, H. P., S. Yang, Y. C. Hsieh, M. A. Choudhry, K. I. Bland, and I. H. Chaudry. 2006. Maintenance of lung myeloperoxidase activity in proestrus females after trauma-hemorrhage: upregulation of heme oxygenase-1. Am.J.Physiol Lung Cell Mol.Physiol 291:L400-L406.
Zhang, Y., M. Adachi, H. Zou, M. Hareyama, K. Imai, and Y. Shinomura. 2006. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int.J.Radiat.Oncol.Biol.Phys. 65:859-866.
|